Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2- dihydropyridono[5,6-g]quinolines

Journal of Medicinal Chemistry

Volumn 41, Issue 4, 1998, Pages 623-639

  Hamann, Lawrence G ^a   Higuchi, Robert I ^a   Zhi, Lin ^a   Edwards, James P ^a   Wang, Xiao Ning ^b   Marschke, Keith B ^b   Kong, James W ^a   Farmer, Luc J ^a,c   Jones, Todd K ^a  

^a Departments of Medicinal Chemistry   (United States)

^b Department of Pharmacology ^*  (United States)

^c VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIHYDRO 2,2,4 TRIMETHYL 6 (TRIFLUOROMETHYL) 8 PYRIDINO[5,6 G]QUINOLINE; 1,2 DIHYDRO 2,2,4,6 TETRAMETHYL 8 PYRIDINO[5,6 G]QUINOLINE; 1,2 DIHYDROPYRIDONO[5,6 G]QUINOLINE DERIVATIVE; 1,2,3,4 TETRAHYDRO 2,2 DIMETHYL 6 (TRIFLUOROMETHYL) 8 PYRIDONO[5,6 G]QUINOLINE; ANDROGEN RECEPTOR; ANTIANDROGEN; FLUTAMIDE; LUTEINIZING HORMONE; MIFEPRISTONE; QUINOLINE DERIVATIVE; TESTOSTERONE; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CANCER HORMONE THERAPY; CASTRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; GENE EXPRESSION; GROWTH INHIBITION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PROSTATE CANCER; RAT; REPORTER GENE; SEMINAL VESICLE; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ANDROGEN ANTAGONISTS; ANIMALS; CELL LINE; COS CELLS; DIHYDROPYRIDINES; DIHYDROTESTOSTERONE; GONADOTROPINS; HETEROCYCLIC COMPOUNDS; HUMANS; INDICATORS AND REAGENTS; MALE; MOLECULAR STRUCTURE; ORCHIECTOMY; PROSTATE; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANDROGEN; RECEPTORS, PROGESTERONE; RECOMBINANT PROTEINS; SEMINAL VESICLES; STRUCTURE-ACTIVITY RELATIONSHIP; TESTOSTERONE; TRANSFECTION;

EID: 0032510051     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970699s     Document Type: Article

References (73)

1. Statistics obtained from NCI SEER database.
2. (a) Stamey, T. A.; Kabalin, J. N.; Ferrari, M.; Yang, N. Prostate Specific Antigen in the Diagnosis and Treatment of Adenocarcinoma of the Prostate: Antiandrogen Treated Patients. J. Urol. 1989, 141, 1088-1090.
3. (b) Duffy, M. J. PSA as a Marker for Prostate Cancer: A Critical Review. Ann. Clin. Biochem. 1996, 33, 511-519.
4. (c) Morote, J.; Raventos, C. X.; Lorente, J. A.; Lopez-Pacios, M. A.; Encabp, G.; de Torres, I.; Andreu, J. Measurement of Free PSA in the Diagnosis and Staging of Prostate Cancer. Int. J. Cancer 1997, 71, 756-759.
5. Luke, M. C., Coffey, D. S. The Male Sex Accessory Tissues. In The Physiology of Reproduction; Knobil, E., Neill, J. D., Eds.; Raven Press: New York, 1994; pp 1435-1487.
6. (a) Evans, R. M. The Steroid and Thyroid Hormone Receptor Superfamily. Science 1988, 240, 889-895.
7. (b) Stein, R. B. In New Drugs From Natural Sources; Coombes, I., James, D., Eds.; IBC Technical Services: Oxford, 1992, p 13.
8. Berger, T. S.; Parandoosh, Z.; Perry, B. W.; Stein, R. B. Interaction of Glucocorticoid Analogues with the Human Glucocorticoid Receptor. J. Steroid Biochem. Mol. Biol. 1992, 41, 733-738.
9. (a) Rosen, J.; Day, A.; Jones, T. K.; Jones, E. T. T.; Nadzan, A. M.; Stein, R. B. Intracellular Receptors and Signal Transducers and Activators of Transcription Superfamilies: Novel Targets for Small-Molecule Drug Discovery. J. Med. Chem. 1995, 38, 4855-4874.
10. (b) Rasmusson, G. H.; Toney, J. H. Chapter 23. Therapeutic Control of Androgen Action. 49n Annual Reports in Medicinal Chemistry; Bristol, J., Ed.; Academic Press: San Diego, 1994; pp 225-234.
11. Walsh, P. C.; Gittes, R. F. Inhibition of Extratesticular Stimuli to Prostatic Growth in the Castrated Rat by Antiandrogens. Endocrinology 1970, 86, 624-627.
12. Labrie, F.; Belanger, A.; Dupont, A.; Luu-The, V.; Simard, J.; Labrie, C. Science Behind Total Androgen Blockade: From Gene to Combination Therapy. Clin. Invest. Med. 1993, 16, 475-492.
13. (a) Habenicht, U. F.; Schroder, H.; El Etreby, M. F.; Neumann, F. Advantages and Disadvantages of Pure Antiandrogens and of Antiandrogens of the Cyproterone Acetate-Type in the Treatment of Prostatic Cancer. In Management of Advanced Cancer of the Prostate and Bladder; Alan R. Liss, Inc.: New York, 1988; pp 63-75.
14. (b) Neumann, F. The Antiandrogen Cyproterone Acetate: Discovery, Chemistry, Basic Pharmacology, Clinical Use and Tool in Basic Research. Exp. Clin. Endocrinol. 1994, 102, 1-32.
15. (a) Beland, G.; Elhilali, M.; Fradet, Y.; Laroche, B.; Ramsey, E. W. Total Androgen Blockade for Metastatic Cancer of the Prostate. Am. J. Clin. Oncol. 1988, 11 (Suppl. 2), S187-S190.
16. (b) Crawford, E. D.; Eisenberger, M. A.; McLeod, D. G.; Spaulding, J. T.; Benson, R.; Dorr, F. A.; Blumenstein, B. A.; Davis, M. A.; Goodman, P. A Controlled Trial of Leuprolide With and Without Flutamide in Prostatic Carcinoma. N. Engl. J. Med. 1989, 321, 419-424.
17. (c) Labrie, F. Mechanism of Action and Pure Antiandrogenic Properties of Flutamide. Cancer 1993, 72,3816-3827.
18. (a) Furr, B. J.; Valcaccia, B.; Curry, B.; Woodburn, J. R.; Chesterson, G.; Tucker, H. ICI 176,334: A Novel Non-Steroidal, Peripherally Selective Antiandrogen. J. Endocrinol. 1987, 113, R7-9.
19. (b) Furr, B. J. A. The Development of Casodex (Bicalutamide): Preclinical Studies. Ear. Urol. 1996, 29 (Suppl. 2), 83-95.
20. Kolvenbag, G. J. C. M.; Blackledge, G. R. P. Worldwide Activity and Safety of Bicalutamide: A Summary Review. Urology 1996, 47 (Suppl. 1A), 70-79.
21. (a) Soloway, M. S.; Matzkin, H. Antiandrogenic Agents as Monotherapy in Advanced Prostatic Carcinoma. Cancer 1993, 71 (Suppl.), 1083-1088.
22. (b) Blackledge, G. R. P. High-Dose Bicalutamide Monotherapy for the Treatment of Prostate Cancer. Urology 1996, 47 (Suppl. 1A), 44-47.
23. Labrie, F.; Dupont, A.; Belanger, A. A New Hormonal Therapy in Prostatic Cancer: Combined Treatment with an LHRH Agonist and Antiandrogen. Clin. Invest. Med. 1982, 2, 267-275.
24. Oesterling, J. E.; Benign Prostatic Hyperplasia: Medical and Minimally Invasive Treatment Options. N. Engl. J. Med. 1995, 332, 99-109.
25. Lucky, A. W. Hormonal Correlates of Acne and Hirsutism. Am. J. Med. 1995, 98 (1A), 89S-94S.
26. Uno, H.; Obana, N.; Cappas, A.; Bonfils, A.; Battmann, T.; Philibert, D. Stimulation of Follicular Regrowth by Androgen Receptor Blocker (RU58841) in Macaque Androgenic Alopecia. In Hair Research for the Next Millenium; van Neste, D.; Randall, V. A., Eds.; Elsevier; Amsterdam, 1996; pp 349-353.
27. (a) Shaw, J. C. Antiandrogen Therapy in Dermatology. Int. J. Dermatol. 1996, 35, 770-778.
28. (b) Leyden, J. J. Therapy for Acne Vulgaris. In Drug Therapy, Wood, A. J. J., Ed.; New Engl. J. Med. 1997, 336, 1156-1162.
29. (a) Wysowski, D. K.; Freiman, J. P.; Tourtelot, J. B.; Horton, M. L., III; Horton, M. L. Fatal and Nonfatal Hepatotoxicity Associated with Flutamide. Ann. Intern. Med. 1993, 118, 860-864.
30. (b) Dawson, L. A.; Chow, E.; Morton, G. Fulminant Hepatic Failure Associated with Bicalutamide. Urology 1997, 49, 283-284.
31. (a) Small, E. J.; Carroll, P. R. Prostate-Specific Antigen Decline After Casodex Withdrawal: Evidence for an Antiandrogen Withdrawal Syndrome. Urology 1994, 43, 408-410.
32. (b) Small, E. J.; Srinivas, S. The Antiandrogen Withdrawal Syndrome. Cancer 1995, 76, 1428-1434.
33. (a) Newmark, J. R.; Hardy, D. O.; Tonb, D. C.; Carter, B. S.; Epstein, J. L; Brown, T. R.; Barrack, E. R. Androgen Receptor Gene Mutations in Human Prostate Cancer. Proc. Nat. Acad. Sci. U.S.A. 1992, 89, 6319-6323.
34. (b) Taplin, M.-E.; Bubley, G. J.; Shuster, T. D.; Frantz, M. E.; Spooner, A. E.; Ogata, G. K.; Keer, H. N.; Balk, S. P. Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer. TV. Engl. J. Med. 1995, 332, 1393-1398.
35. (c) Tilley, W. D.; Buchanan, G.; Hickey, T. E.; Bentel, J. M. Mutations in the Androgen Receptor Gene Are Associated with Progression of Human Prostate Cancer to Androgen Independence. Clin. Cancer Res. 1996, 2, 1-9.
36. Scher, H. I.; Zhang, Z. F.; Nanus, D.; Kelly, W. K. Hormone and Antihormone Withdrawal: Implications for the Management of Androgen-Independent Prostate Cancer. Urology 1996, 47 (Suppl. 1A), 61-69.
37. (a) Jones, T. K.; Pathirana, C.; Goldman, M. E.; Hamann, L. G.; Farmer, L. J.; laniro, T.; Johnson, M. G.; Bender, S. L.; Mais, D. E.; Stein, R. B. Discovery of Novel Intracellular Receptor Modulating Drugs. J. Steroid Biochem. Mol. Biol. 1996, 56, 61-66.
38. (b) Pathirana, C.; Stein, R. B.; Berger, T. S.; Fenical, W.; laniro, T.; Mais, D. E.; Torres, A.; Goldman, M. E. Nonsteroidal Human Progesterone Receptor Modulators from the Marine Alga, Cymopolia barbata. Mol. Pharmacol. 1995, 47, 630-635.
39. (c) Hamann, L. G.; Farmer, L. J.; Johnson, M. G.; Bender, S. L.; Mais, D. E.; Goldman, M. E.; Wang, M.-W.; Crombie, D.; Jones, T. K. Synthesis and Biological Activity of Novel Non-Steroidal Progesterone Receptor Antagonists Based on Cyclocymopol Monomethyl Ether. J. Med. Chem. 1996, 39, 1778-1789.
40. (a) Hollenberg, S. M.; Evans, R. M. Multiple and Cooperative Trans-Activation Domains of the Human Glucocorticoid Receptor. Cell 1988, 55, 899-906.
41. (b) Simental, J. A.; Sar, M.; Lane, M. V.; French, F. S.; Wilson, E. M. Transcriptional Activation and Nuclear Targeting Signals of the Human Androgen Receptor. J. Biol. Chem. 1991, 266, 510-518.
42. (a) Jones, G. Quinolines. In The Chemistry of Heterocyclic Compounds; Weissberger, A., Taylor, E. C., Eds.; Wiley Interscience: New York, 1977; pp 136-181, 259-299.
43. (b) Easton, N. R.; Cassady, D. R. A Novel Synthesis of Quinolines and Dihydroquinolines. J. Org. Chem. 1962, 27, 4713-4714.
44. (c) Williamson, N. M.; March, D. R.; Ward, A. D. An Improved Synthesis of 2,2-Disubstituted-1,2-dihydroquinolines and their Conversion to 3-Chloro-2,2-disubstituted-tetrahydroquinolines. Tetrahedron Lett. 1995, 36, 7721-7724.
45. (a) Manske, R. H. F.; Kulka, M. The Skraup Synthesis of Quinolines. Org. React. 1953, 7, 59-98.
46. (b) Walter, H.; Sauter, H.; Winkler, T. A New and Simple Method for the Synthesis of Spirocyclic 1H Quinolines. Helu. Chim. Acta 1992, 75, 1274-1280.
47. (c) Eisch, J. J.; Dluzniewski, T. Mechanism of the Skraup and Doebner-von Miller Quinoline Syntheses: Cyclization of α,β-Unsaturated N-Aryliminium Salts via 1,3-Diazetidinium Ion Intermediates. J. Org. Chem. 1989, 54, 1269-1274.
48. (d) Johnson, J. V.; Rauckman, B. S.; Baccanari, D. P.; Roth, B. 2,4-Diamino5-benzylpyrimidines and Analogues as Antibacterial Agents. 12. 1,2-Dihydroquinolylmethyl Analogues with High Activity and Specificity for Bacterial Dihydrofolate Reductase. J. Med. Chem. 1989, 32, 1942-1949.
49. (a) Knorr, L. Liebigs Ann, 1886, 236, 69.
50. (b) Hodgkinson, A. J.; Staskun, B. J. Org. Chem. 1969, 34, 1709-1713.
51. (c) Bergstrom, F. W. Chem. Rev. 1944, 35, 157.
52. (d) Bergstrom, F. W. Chem. Rev. 1948, 48, 47.
53. (e) Hauser, C. R.; Reynolds, G. A. Reactions of β-Keto Esters with Aromatic Amines. Synthesis of 2- and 4-Hydroxyquinoline Derivatives. J. Am. Chem. Soc. 1948, 70, 2402-2404.
54. (a) Imada, Y.; Yuasa, M.; Nakamura, I.; Murahashi, S.-I. Copper(I)-Catalyzed Amination of Propargyl Esters. Selective Synthesis of Propargylamines, 1-Alken-3-ylamines, and (Z)-Allylamines. J. Org. Chem. 1994, 59, 2282-2284.
55. (b) Hennion, G. F.; Kanzel, R. S. The Alkylation of Amines with t-Acetylenic Chlorides. Preparation of Sterically Hindered Amines. J. Am. Chem. Soc. 1960, 82, 4908-4912.
56. Gribble, G. W.; Nutaitis, C. F. Reactions of Sodium Borohydride in Acidic Media; XVI. N-Methylation of Amines with Paraformaldehyde/Trifluoroacetic Acid. Synthesis 1987, 709-711.
57. Imamoto, T.; Takiyama, N.; Nakamura, K.; Hatajima, T.; Kamiya, Y. Reactions of Carbonyl Compounds with Grignard Reagents in the Presence of Cerium Chloride. J. Am. Chem. Soc. 1989, 111, 4392-4398.
58. (a) Sato, T.; Yoshimatsu, K.; Otera, J. CsF in Organic Synthesis. Tuning of N- or O-Alkylation of 2-Pyridone. Synlett 1995, 845-846.
59. (b) Beak, P. Energies and Alkylations of Tautomeric Heterocyclic Compounds: Old Problems-New Answers. Acc. Chem. Res, 1977, 10, 186-192.
60. (c) Liu, H.; Ko, S.-B.; Josien, H.; Curran, D. P. Selective N-Functionalization of 6-Substituted-2-Pyridones. Tetrahedron Lett, 1995, 36, 8917-8920.
61. (a) Rathore, R.; Saxena, N.; Chandrasekaran, S. A Convenient Method of Benzylic Oxidation with Pyridinium Chlorochromate. Synth. Commun. 1986, 16, 1493-1498.
62. (b) Parish, E. J.; Chitrakorn, S.; Wei, T.-Y. Pyridinium Chlorochromate-Mediated Allylic and Benzylic Oxidation. Synth. Commun. 1986, 16, 1371-1375.
63. Data not shown.
64. Okuda, Y.; Fujisawa, M.; Matsumoto, O.; Kamidono, S. Testosterone Dependent Regulation of the Enzymes Involved in DNA Synthesis in the Rat Ventral Prostate. J. Urol. 1991, 145, 188-191.
65. Haisenleder, D. J.; Dalkin, A. C.; Marshall, J. C. Regulation of Gonadotropin Gene Expression. In The Physiology of Reproduction; Knobil, E., Neill, J. D., Eds.; Raven Press: New York, 1994; pp 1793-1813.
66. Freeman, S. N.; Mainwaring, W. I. P.; Furr, B. J. A. A Possible Explanation for Peripheral Selectivity of a Novel Non-Steroidal Pure Antiandrogen, Casodex (ICI 176,334). Br. J. Cancer 1989, 60, 664-668.
67. Chandolia, R. K.; Weinbauer, G. F.; Simoni, M.; Behre, H. M.; Nieschlag, E. Comparative Effects of Chronic Administration of the Non-Steroidal Antiandrogens Flutamide and Bicalutamide on the Reproductive System of the Adult Male Rat. Acta Endocrinol. (Copenhagen) 1991, 125, 547-555.
68. (a) Veldschote, J.; Berrevoets, C. A.; Ris-Stalpers, C.; Kuiper, G. G. M.; Jenster, G.; Trapman, J.; Brinkmann, A. O.; Mulder, E. The Androgen Receptor in LNCaP Cells Contains a Mutation in the Ligand Binding Domain Which Affects Steroid Binding Characteristics and Response to Antiandrogens. J. Steroid. Biochem. Mol. Biol. 1992, 41, 665-669.
69. (b) Berrevoets, C. A.; Veldscholte, J.; Mulder, E. Effects of Antiandrogens on Transformation and Transcription Activation of Wild-Type and Mutated (LNCaP) Androgen Receptors. J. Steroid. Biochem. Mol. Biol. 1993, 46, 731-736.
70. (c) Veldscholte, J.; Berrevoets, C. A.; Mulder, E. Studies on the Human Prostatic Cancer Cell Line LNCaP. J. Steroid. Biochem. Mol. Biol. 1994, 49, 341-346.
71. (d) Gaddipati, J. P.; McLeod, D. G.; Heidenberg, H. E.; Sesterhenn, I. A.; Finger, M. J.; Moul, J. W.; Srivastava, S. Frequent Detection of Codon 877 Mutation in the Androgen Receptor Gene in Advanced Prostate Cancers. Cancer Res. 1994, 54, 2861-2864.
72. Data not shown.
73. Still, W. C.; Kahn, M.; Mitra, A. Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution. J. Org. Chem. 1978, 43, 2923-2925.